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Abstract
Purpose To determine the factors that affect oocyte extraction
efficiency when using the “combined procedure”. In the pres-
ent “combined procedure” ovarian tissue cryopreservation
and oocyte extraction from an isolated ovary, later used in In
Vitro Maturation (IVM), are performed concurrently.
Methods Data were analyzed retrospectively and obtained
from the clinical records of 27 young breast cancer patients
referred for fertility preservation.
Results The patients’ mean age was 33.7 (±3.8) years, mean
serum anti-Müllerian hormone (AMH) concentration was 3.5
(±2.1) ng/ml, and mean number of extracted oocytes was 8.3
(±6.1). The phase of menstruation (follicular or luteal) did not
affect either the number of oocytes extracted (P=0.99) nor
oocyte survival or maturation rates. Likewise, the number of
oocytes that could be extracted was not affected by the type of
laparoscopic procedure (multiple-port or single-incision lapa-
roscopy; P=0.94) or the molecular subtype of breast cancer
(either Luminal A or B; P=0.52). Analysis revealed that the
number of extracted oocytes was well-correlated with the
patient’s AMH serum level and age (coefficient of correlation:
0.60 and −0.48, respectively).
Conclusion We conclude that the outcome of the “combined
procedure” primarily depends upon the patient’s serum AMH
level and age. Importantly, the “combined procedure”may be
used during any phase of the menstrual cycle to preserve the
fertility of breast cancer patients.
Keywords Combined procedure . Ovarian tissue
cryopreservation . Oncofertility . Fertility preservation .
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Introduction
The number of young breast cancer patients who desire to bear
children has increased in Japan [1]. This trend is likely due to
the increasing incidence of breast cancer and the tendency of
young women to marry later. Therefore, fertility preservation
for young breast cancer patients has become a significant
medical concern. Although it is not easy to assess the degree
of gonadal damage, the level of ovarian dysfunction depends
upon the patient’s age, the type and regimen of chemotherapy,
and drug dosage. Chemotherapy for the treatment of breast
cancer may induce amenorrhea or premature ovarian failure
(POF) [2]. In breast cancer patients aged >40 years, the front
line chemotherapy regimen AC or AC-T (anthracycline and
cyclophosphamide, and taxane) could decrease ovarian re-
serve. Although CMF (cyclophosphamide and methotrexate
and 5-FU) is not first line treatment, it could induce POF for
more than half of breast cancer patients aged 30–39 years. In
addition, the effect of taxane on ovarian reserve is still con-
troversial. Of the 242 breast cancer patients who were admin-
istered AC or trastuzumab and paclitaxel, paclitaxel did not
increase the risk of amenorrhea [3]. However, the increased
risk of POF caused by taxane has been considered [4].
Capsule “Combined procedure” is effective procedure for young cancer
female patients who hope to preserve her fertility. The outcome of
“combined procedure” depends upon the serum AMH level and
patient’s age. In addition, the outcome was not affected menstrual cycle.
Therefore, patients can receive “combined procedure” regardless of
menstrual cycle.
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For breast cancer patients who are at risk for POF, due to
chemotherapy, there are three options for fertility preservation.
According to the 2nd guideline of the American Society of
Clinical Oncology (ASCO) for fertility preservation, embryo
and oocyte cryopreservation are established methods for fertility
preservation; however, the third option of ovarian tissue cryo-
preservation is experimental and not yet an established method
[5]. Although embryo and oocyte cryopreservation are
established methods, many cancer patients cannot utilize these
options because either oocyte extraction would require delaying
chemotherapy or because their cancer is an estrogen-dependent
type. FertiPROTEKT suggests ovarian tissue cryopreservation
as a fertility preservation option for cancer patients who have too
short a time (less than two weeks) before chemotherapy for
embryo and/or oocyte cryopreservation [6]. At present, there
have been around 30 live births from transplanted ovarian tissue.
In addition, Kawamura et al. recently investigated the vitrifica-
tion methods of ovary tissue cryopreservation and reported two
cases of pregnancy using oocytes from vitreous-warmed ovarian
tissue [7, 8]. Ovarian tissue cryopreservation is advantageous for
breast cancer patients because they may be able to reserve many
follicles within a few days. Furthermore, some researchers have
reported the efficacy of a combined procedure in which various
fertility preservation methods are combined [9–11]. In the
present “combined procedure” ovarian tissue cryopreservation
and oocyte extraction from an isolated ovary, later used IVM,
are performed concurrently.
In present study, we seek to elucidate the factors that
correlated to the efficacy of “combined procedure” on young
breast cancer patients who received ovarian tissue cryopres-
ervation for fertility preservation.
Materials and methods
Patients
Data were retrospectively obtained from the clinical records of
breast cancer patients who were referred to the Oncofertility
Unit at the Center for Reproductive Medicine, Department of
Obstetrics and Gynecology of our university hospital from
February 2010 toMarch 2014. In the current study, all patients
gave written, informed consent in keeping with the Declara-
tion of Helsinki, and the study was approved by the institu-
tional review board of university. We decided the procedure of
fertility preservation (oocyte and embryo cryopreservation, or
ovary tissue cryopreservation) according to period until che-
motherapy and age of patient. Mostly patients who received
ovary tissue cryopreservation had not enough time for oocyte
(or embryo) cryopreservation. And also, some patients who
lived in province far from our institution chose ovary tissue
preservation. Of course, before made their mind, all patients
were given information about the rate of conception after
treatment of breast cancer. And also, we told them the risk
that ovarian reserve could be decreased by ovariectomy and
the risk of dysfunction of ovary tissue after thawing, especial-
ly on diminished ovarian reserve patients. In addition, we have
explained about contamination of minimum residual disease.
Especially for BRCA 1/2 mutation carrier patients (mainly
triple negative type breast cancer patients), the fact that the
ovary tissue had potential risk of ovarian cancer was informed.
Data collection
Drawing from clinical records, data were collected on the
following epidemiological parameters for breast cancer pa-
tients: the patient’s age, body mass index (BMI), marital
status, phase of menstruation (follicular or luteal) at the time
of operation, level of anti-Müllerian hormone (AMH) at the
time of first visit to our hospital, phenotype of breast cancer,
whether the patient received treatment for breast cancer before
ovary tissue cryopreservation, and laparoscopic surgical pro-
cedure (multiple-port laparoscopy or single-incision laparos-
copy). SerumAMH levels were measured using a commercial
assay kit (AMH Gen II ELISA, BECKMAN COULTER,
Brea, CA, USA) according to the manufacturer’s protocol.
The detection limit of this kit was 0.16 ng/ml.
Surgical techniques
Of the 27 patients examined, 16 underwent multiple-port lapa-
roscopy and 11 underwent single-incision laparoscopy. During
laparoscopy, a 5-mm scope (HOPKINS 30 K 260468A, Im-
age1 H3-Z K2220055-3; KARL STORZ, Tuttlingen, Germa-
ny) was used to secure the field of vision. An incision was
made in the umbilical region using a closed approach for entry
into the peritoneal cavity. A 5-mm trocar (ENDOPATH
EXCEL Trocars; ETHICON Endo-Surgery, JOHNSON
AND JOHNSON, NJ, USA) was inserted into the umbilical
region to accommodate the 5-mm scope. Then, 5-mm and
11 mm trocars were inserted into the left inguinal and midline
regions of the abdominal wall under the laparoscope. The E-Z
ACCESS (FF07; HAKKO, Nagano, JAPAN) and LAP PRO-
TECTOR (FF0707; HAKKO, Nagano, JAPAN) were used for
single-incision laparoscopy. A 2 cm incision was made at edge
of the umbilicus and the open method was used to place the E-
Z ACCESS so it would reach the peritoneal cavity. Three 5-
mm ports (E-Z trocar smart insertion S701 V12, E-Z trocar
smart insertion S701 CV12; HAKKO, Nagano, JAPAN) were
inserted into the E-Z ACCESS. Hemilateral ovariectomy for
ovarian cryopreservation was performed during multiple-port
or single-port laparoscopic surgery. After minimal thermo-
coagulation using Bipolar (Bicoag E23-0003 3600, AMCO,
Tokyo, Japan) to prevent hemorrhaging, the hemilateral whole
ovary was extracted by severing the ovarian arteries and veins
and the associated ligaments of the ovary using scissor forceps.
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After the hemilateral whole ovary was extracted, sites of
bleeding were cauterized tightly to stop bleeding, including
ovarian vessels and ligaments. Then extracted whole ovary
was placed in saline solution at 37 °C and immediately
transported to a tissue culture room.
Ovarian tissue preparation
Isolatedwhole ovaries were cut into two identical halves using
a surgical knife. Then the medulla was isolated from the rest of
the ovary using surgical scissors. Following isolation of the
medulla, the ovarian cortical tissue was divided into segments
(approx. 10 mm×10 mm×1 mm) using a surgical knife. The
pieces were used for ovarian tissue cryopreservation. This
process was performed in a petri dish (Bateriological Petri
Dish 60x15 mm, FALCON 351007; Becton, Dickinson and
Company, NJ, USA) containing mHTF culture medium (with
Hepes; KITAZATO Biopharma Co., Ltd. Shizuoka, Japan)
supplemented with 10 % SSS (Serum Substitute Supplement
not for Injection, IRVINE, Santa Ana, CA, USA) pre-warmed
to 37 °C. Following vitrification [7, 8], ovarian tissue sections
were stored in liquid nitrogen for fertility preservation.
Oocyte extraction
The process of oocyte extraction was carried out in two-steps.
First, oocytes were extracted by follicle fluid aspiration from
ovarian tissue using a 22-gauge needle (JS-NS2232SP; JMS





















1 34 Single None 23.7 F (6) 4.2 17 18 Multiple A
2 33 Married None 25 L (22) 6.90 11 12 Multiple B FEC*4 DOC/
HCN*4
3 32 Single None 19 F (6) 3.16 12 28 Multiple B
4 39 Single None 20.8 F (3) 3.98 5 16 Multiple A Radiation
5 39 Married None 19.2 F (4) 1.57 4 18 Multiple B
6 29 Married None 23.1 F (3) 5.82 19 26 Multiple B
7 33 Married 1G1P 30.6 F (7) 3.06 2 16 Multiple B
8 30 Single None 23.8 L (22) 6.62 7 15 Multiple B
9 36 Single None 201 F (6) 1.37 7 17 Multiple B GnRHa 2y,
TAM 5y
10 41 Married 1G0P 32.8 L (17) 0.72 4 9 Multiple B
11 36 Single 1G0P 18.2 unknown 1.45 5 20 Multiple B
12 35 Single None 19.4 F (7) 0.87 0 22 Multiple B
13 33 Single None 19.7 L (28) 6.13 26 23 Multiple B
14 33 Single None 19.9 L (25) 2.05 9 18 Multiple A
15 34 Married None 18.9 F (9) 1.09 0 20 Multiple B CE*4 DOC/
HCN*4
16 32 Single None 19.5 F (8) 4.35 14 17 Multiple HER2
17 34 Single None 20.1 L (16) 2.21 6 12 Single Tri neg
18 37 Married None 17.7 L (25) 0.7 2 15 Single A TAM 2 M
19 36 Married 1G0P 23.9 L (32) 3.03 10 6 Single B
20 29 Single None 19.6 unknown 5.2 6 19 Single B
21 33 Married 3G0P 20.2 F (14) 5.31 9 17 Single B surgery
22 38 Married 1G0P 24.5 F (8) 0.52 10 8 Single B
23 34 Single None 21.1 F (13) 3.56 2 11 Single A
24 36 Single None 22.3 L (23) 3.82 5 14 Single B
25 34 Single None 18.6 F (3) 5.51 9 14 Single B
26 25 Single None 17.6 F (6) 7.73 17 14 Single B
27 25 Single 1G0P 19 L (29) 2.54 8 16 Single B
F Follicular phase, L Luteal phase, Multiple multiple port surgery, Single Single port laparoscopy, A Luminal A type, B Luminal B type, Tri neg triple
negative type, TAM tamoxifen, FEC 5-FU and epirubicin and cyclophosphamide, DOC docetaxel, HCN trastuzumab, CE cyclophosphamide and
epirubicin, GnRHa gonadotropin releasing hormone agonist
J Assist Reprod Genet (2015) 32:305–312 307
Co. Hiroshima, Japan) and a 2.5 ml syringe (SS-02Sz;
TERMO Co., Tokyo, JAPAN). Second, under a stereo micro-
scope (M165C-SM; LEICA, Solms, Germany) oocytes were
identified and collected from the medium using a 200 μl pipet
(Calibrated pipet 2-000-200; DRUMMOND SIENTIFIC
COMPANY, PA, USA) for ovarian tissue preparation. We
collected the oocyte as many as possible by aspiration from
all follicles including small antral follicles without measure-
ment of follicle diameter.
In vitro maturation of oocytes
IVM of oocytes extracted from ovarian tissue germinal vesi-
cles was carried out using IVM medium (IVM system
82214010A; ORIGIO, Malov, Denmark) containing 10 %
SSS (Serum Substitute Supplement not for Injection, IRVINE,
Santa Ana, CA, USA) and 37.5 mIU/ml of FSH (Gonalef;
MERCK SERONO, Darmstadt, Germany). After an incuba-
tion of 24–48 h at 37 °C, atmosphere of 5 % CO2, and 5 % O2
in a high humidity culture, we assessed oocyte maturation.
Oocyte maturation was determined microscopically by ob-
serving the extrusion of the first polar body into the
perivitelline space, which denotes maturation to the meta-
phase II (MII) stage. Conversely, oocytes that exhibited a
morphological change or turned brownish were determined
to be degenerated oocytes.
Statistical analysis
Data analysis was performed using the Statistics Package for
Social Sciences (SPSS 11.0, Chicago, IL). To investigate the
correlations between patient AMH levels, age, BMI, ovarian
tissue volume, and the number of extracted oocytes, we used a
non-parametric Spearman’s correlation coefficient by rank
test. To investigate the impact of various epidemiological
factors (especially phase of menstrual cycle) on the number
of oocytes, survival rate (total oocytes extracted minus the
number of degenerated oocytes / total oocytes extracted), and
maturation rate (MIIoocytes / total extracted oocytes minus
the degenerated oocytes), we used a non-parametric Mann-
Whitney’s U test; P <0.05 was considered statistically
significant.
Results
The number of young breast cancer patients who underwent
procedures for ovarian tissue cryopreservation was 27. The
mean age of patients was 33.7 (±3.8) years. There were no
polycystic ovary syndrome patients, and all patients had reg-
ular menstrual cycles prior to treatment. Ten patients were
married, and 17 were single. Of note, 20 had never been
pregnant while 7 had experienced pregnancy. The average
body mass index (BMI) was 21.4 (±3.6). Fifteen patients
underwent surgery during the follicular phase of the menstrual
cycle (before ovulation), 10 patients underwent surgery during
the luteal phase of the menstrual cycle (post-ovulation), and
for the remaining 2 patients the menstrual stage was unknown.
None of the patients were in the ovulation phase. The patients’
molecular subtype of breast cancer were as follows: 5 were
luminal A, 20 were luminal B, and one was basal-like type;
therefore, one was HER 2 type. The average AMH level was
3.5 (±2.1) ng/ml. The average number of extracted oocytes
was 8.3 (±6.1), and the number of ovarian tissue pieces
obtained was 16.3 (±5.1). Two of the patients underwent
chemotherapy and one underwent surgery prior to ovarian
tissue cryopreservation. Sixteen underwent multiple-port lap-
aroscopy and eleven underwent single-port laparoscopy for
Fig. 1 The correlation between
the menstrual cycle phase and the
number of extracted oocytes.
With regard to phase in the
menstrual cycle, there was no
significant difference between
groups in the number of extracted
oocytes (P=0.99 non-parametric
Mann-Whitney’s U test)
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ovarian tissue cryopreservation. Detailed data regarding indi-
vidual patients is shown in Table 1.
With regard to the phase in the menstrual cycle (P=0.99)
(Fig. 1), laparoscopic procedure (P=0.94) (Fig. 2a), marital
status (P=0.47), previous pregnancy experience (P=0.68),
molecular subtype of breast cancer (comparing only Luminal
A to B) (P=0.52), there was no significant difference between
the groups in the number of oocytes extracted. In Fig. 2a we
show that there was no significant difference in AMH levels
with regard to laparoscopic procedure (P=0.88) (Fig. 2a).
And also, there was no significant difference in terms of the
survival and maturation rates between the follicular phase and
the luteal phase (Table 2). Patients 11 and 20 were excluded
from Table 2 because their phase in the menstrual cycle was
unknown at the time of surgery. Furthermore, we found that
the patient’s AMH level and the number of extracted oocytes
was well-correlated (coefficient of correlation: 0.60) (Fig. 2b).
Also, the age at which the ovarian tissue was cryopreserved
and the number of extracted oocytes was correlated (coeffi-
cient of correlation: −0.48) (Fig. 3). However, we did not find
any correlation between BMI or the number of ovarian tissue
segments and the number of extracted oocytes (coefficient of
correlation: 0.08, 0.10, respectively).
Discussion
In a typical IVM cycle, the number of available oocytes is the
most significant factor associated with a successful procedural
outcome in normo-ovulatory patients [12]. Therefore, it is
a
b
Fig. 2 The correlation between
patient AMH level and the
number of extracted oocytes. a
With regard to laparoscopic
procedure, there was no
significant difference between
groups in the number of extracted
oocytes and AMH levels (P=
0.94, 0.88 respectively. non-
parametric Mann-Whitney’s U
test). b A strong correlation was
observed between AMH levels
and the number of extracted
oocytes (correlation coefficient:
0.60, Spearman’s correlation
coefficient by rank test)
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necessary to elucidate the factors associated with the number
of oocytes obtained from the “combined procedure” for
oncofertility treatment. In a previous report, researchers found
that patients’AMH levels and the number of extracted oocytes
were well-correlated in the 80 patient normo-ovulately group
(mean age; 31.5±5, mean AMH level; 2.7±2.5 ng/ml, mean
BMI 22±2) and the 20 patient polycystic ovary syndrome
group (mean age; 29±4, mean AMH level; 8.4±4 ng/ml,
mean BMI 23±2) [13]. In both groups, there was a strong,
positive correlation between patients’ AMH levels and the
number of extracted oocytes. There was also a negative cor-
relation between age and the number of extracted oocytes
[13]. These previous findings are congruent with the current
study. Therefore, we conclude that the number of oocytes
extracted from cryopreserved ovarian tissue is well-
correlated with the breast cancer patients’ AMH levels and
age at the time of surgery.
Previously it was shown that the stage of menstruation
(follicular or luteal phase) did not significantly affect either
the number of oocytes collected, the total number of MII
oocytes, or the maturation rate of oocytes in a hormone-
stimulated, follicle stimulating hormone (FSH) and human
chorionic gonadotropin (hCG), IVM cycle [14]. Furthermore,
consistent with the present study, the researchers reported that
the number of immature oocytes that could be retrieved from a
partially excised ovary did not depend upon the menstrual
Table 2 The comparison of the IVM results from the follicular and luteal phases
Phase No. Total MII MI GV Deg. SRa (%) MRb (%)
Follicular 1 17 7 4 2 4 76.5 53.8
3 12 1 4 4 3 75 11.1
4 5 1 4 0 0 100 20
5 4 3 0 0 1 75 100
6 19 4 6 3 6 68.4 30.8
7 2 0 2 0 0 100 0
9 7 3 2 0 2 71.4 60
12 0 - - - - - -
15 0 - - - - - -
16 14 6 3 2 3 78.6 54.5
21 9 6 0 2 1 88.9 75
22 10 3 3 1 3 70 42.9
23 2 1 0 0 1 50 100
25 9 7 1 1 0 100 77.8
26 17 9 3 2 3 82.4 64.3
mean 8.5(±6.3) 3.9(±2.8) 2.5(±1.9) 1.3(±1.3) 2.1(±1.8) 79.7(±14.6) 53.1(±31.6)
No. Total MII MI GV Deg. SR (%) MII rate (%)
Luteal 2 11 4 5 1 1 90.9 40.0
8 7 4 2 1 0 100 57.1
10 4 2 1 0 1 75 66.7
13 26 13 7 1 5 80.8 61.9
14 9 2 3 1 3 66.7 33.3
17 6 3 2 0 1 83.3 60
18 2 0 0 0 2 0 -
19 10 2 5 1 2 80 25
24 5 2 1 0 2 60 66.7
27 8 0 5 0 3 62.5 0
Mean 8.8(±6.6) 3.2(±3.7) 3.1(±2.3) 0.5(±0.5) 2(±1.4) 69.9(±27.5) 45.6(±22.9)
P value 0.99 0.37 0.53 0.16 0.98 0.51 0.66
Values are expressed mean±SD
No. patient number, Deg. degeneration oocyte, SR survival rate, MR maturation rate
a survival rate=total oocytes extracted minus the number of degenerated oocytes / total oocytes extracted)
bmaturation rate=MIIoocytes / total extracted oocytes minus the degenerated oocytes)
Qualitative data were expressed as numbers and compared using the non-parametric Mann-Whitney’s U test. (P<0.05)
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phase when using the “combined procedure” [11]. In a study
of an unstimulated IVM cycle, oocytes were retrieved in both
the luteal and the follicular phases [15]. Likewise, collection
during the follicular or luteal phase using the “combined
procedure” produced similar results and was not significantly
different. In a nonhuman primate (baboon) IVM study, there
was a maturation rate >40 % using oocytes extracted from the
ovary during the luteal phase [16]. Whereas, a bovine IVM
study revealed that the number of oocytes retrieved from the
luteal phase ovary was less than number of oocytes retrieved
from the early follicular phase; although, it should be noted
that there was no significant difference in terms of the matu-
ration rate or the number of degenerated oocytes [17]. Though
the data support the efficacy of the “combined procedure”
during any menstrual phase, a larger-scale human study is
needed to clarify the true efficacy of “combined procedure”
during the luteal phase of menstruation. This study should
highlight the fertility and pregnancy rates of women after
treatment.
In the present study, 2 patients had undergone chemother-
apy, and another 2 patients were undergoing gonadal suppres-
sion therapy using gonadotropin releasing hormone agonist
(GnRHa) with tamoxifen. As mentioned above, the chemo-
therapy containing cyclophosphamide for breast cancer has an
adverse effect on ovarian reserve. Although we could not
determine the effect of chemotherapy with only four patients,
we can extract oocytes in accordance with the AMH levels in
similar patients who undergo treatment for breast cancer. A
larger scale study is needed to assess the effect of chemother-
apy and GnRHa on the outcome of the “combined procedure”.
The number of extracted oocytes in this study was 8.2
(±6.0) (range; 0–26). According to previous reports, the range
of the collected oocytes from a bilateral ovaries isolation and
the “combined procedure” was “0 to 10” and “1 to 4”, respec-
tively [18, 19]. Consequently, we conclude that our procedure
for oocyte collection was appropriate. In comparison to pre-
vious reports [18, 19], our method is safer and is a minimally
invasive technique; our method does not require trans-vaginal
or trans-abdominal oocyte pick up. Although single-port lap-
aroscopy is a more difficult surgical procedure than multiple-
port laparoscopy, postoperative recovery is faster for single-
port laparoscopy because it requires only one small incision
[18]. In present study, there was no significant difference
between the surgical procedure type and the number of oo-
cytes that could be extracted. Therefore, the type of surgical
procedure chosen depends on the condition of adhesion, that
is, with or without endometriosis [18].
In conclusion, the outcome of the “combined procedure”
depends upon the patient’s AMH level and age. Although
random-start controlled ovarian hyperstimulation was report-
ed recently as successful emergency fertility preservation
method [20–22], the method is not yet widespread. Until it
becomes more widely available, the “combined procedure”
can be used in any phase of the menstrual cycle to preserve the
fertility of breast cancer patients. In addition, it is need to
clarify the effect of “combined procedure” including assess-
ment of fertility rate and live birth rate based on more large
scale study.
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